Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 2/20 | 0.54 |
| ▸ | TSHR | P16473 | 1/20 | 0.54 |
| ▸ | PI4KA | P42356 | 4/20 | 0.54 |
| ▸ | PI4K2B | Q8TCG2 | 4/20 | 0.54 |
| ▸ | PI4K2A | Q9BTU6 | 4/20 | 0.54 |
| ▸ | PI4KB | Q9UBF8 | 4/20 | 0.54 |
| ▸ | TP53 | P04637 | 1/20 | 0.54 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.54 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.54 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.54 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.54 |
| ▸ | MEN1 | O00255 | 1/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.54 |
| ▸ | APEX1 | P27695 | 1/20 | 0.54 |
| ▸ | BLM | P54132 | 1/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.54 |
| ▸ | ADCY1 | Q08828 | 1/20 | 0.54 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.54 |
| ▸ | NPC1 | O15118 | 1/20 | 0.53 |
| ▸ | RAB9A | P51151 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4063305 | 0.84 | CYP1A2 (0.53) | CYP1A2TSHRPI4KAPI4K2BPI4K2A | |
| SCHEMBL4122030 | 0.84 | NPC1 (0.60) | CYP1A2TSHRPI4KAPI4K2BPI4K2A | |
| SCHEMBL4134543 | 0.82 | CYP2C19 (0.57) | CYP1A2TSHRPI4KAPI4K2BPI4K2A | |
| SCHEMBL4067215 | 0.80 | NPC1 (0.57) | CYP1A2TSHRPI4KAPI4K2BPI4K2A | |
| SCHEMBL4070092 | 0.80 | NPC1 (0.54) | CYP1A2TSHRPI4KAPI4K2BPI4K2A | |
| SCHEMBL4063885 | 0.79 | CYP1A2 (0.56) | CYP1A2TSHRPI4KAPI4K2BPI4K2A | |
| SCHEMBL22111671 | 0.77 | CYP2C19 (0.51) | CYP1A2TSHRPI4KAPI4K2BPI4K2A | |
| SCHEMBL22111670 | 0.75 | CYP2C19 (0.52) | CYP1A2TSHRPI4KAPI4K2BPI4K2A | |
| SCHEMBL14964635 | 0.75 | PI4KA (0.60) | CYP1A2TSHRPI4KAPI4K2BPI4K2A | |
| SCHEMBL675830 | 0.75 | PI4KA (0.92) | CYP1A2TSHRPI4KAPI4K2BPI4K2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090253718-A1 | Pharmaceutical Compounds | ASTEX THERAPEUTICS LIMITED (GB) | 2009-10-08 | — | — | US | disclosed |
| US-20090253718-A1 | Pharmaceutical Compounds | ASTEX THERAPEUTICS LIMITED (GB) | 2009-10-08 | — | — | US | disclosed |
| US-20090253718-A1 | Pharmaceutical Compounds | ASTEX THERAPEUTICS LIMITED (GB) | 2009-10-08 | — | — | US | disclosed |
| US-20090099213-A1 | Ortho-Condensed Pyridine and Pyrimidine Derivatives (e.g., Purines) as Protein Kinases Inhibitors | ASTEX THERAPEUTICS LIMITED (GB) | 2009-04-16 | — | — | US | disclosed |
| US-20090099213-A1 | Ortho-Condensed Pyridine and Pyrimidine Derivatives (e.g., Purines) as Protein Kinases Inhibitors | ASTEX THERAPEUTICS LIMITED (GB) | 2009-04-16 | — | — | US | disclosed |
| US-20090099213-A1 | Ortho-Condensed Pyridine and Pyrimidine Derivatives (e.g., Purines) as Protein Kinases Inhibitors | ASTEX THERAPEUTICS LIMITED (GB) | 2009-04-16 | — | — | US | disclosed |
| EP-2016077-A2 | PHARMACEUTICAL COMPOUNDS | Astex Therapeutics Limited (GB) | 2009-01-21 | — | — | EP | disclosed |
| WO-2007125315-A2 | PHARMACEUTICAL COMPOUNDS | ASTEX THERAPEUTICS LIMITED (GB) | 2007-11-08 | — | — | WO | disclosed |
| WO-2007125315-A2 | PHARMACEUTICAL COMPOUNDS | ASTEX THERAPEUTICS LIMITED (GB) | 2007-11-08 | — | — | WO | disclosed |
| EP-1812003-A1 | ORTHO- CONDENSED PYRIDINE AND PYRIMIDINE DERIVATIVES (E. G. PURINES) AS PROTEIN KINASES INHIBITORS | Astex Therapeutics Limited (GB) | 2007-08-01 | — | — | EP | disclosed |
| WO-2006046023-A1 | ORTHO- CONDENSED PYRIDINE AND PYRIMIDINE DERIVATIVES (E. G. PURINES) AS PROTEIN KINASES INHIBITORS | ASTEX THERAPEUTICS LIMITED (GB) | 2006-05-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090253718-A1 | Pharmaceutical Compounds | GRK3, CNKSR1, CSNK1G3 | CYP1A2 1220/4885TSHR 165/4885PI4KA 1992/4885 |
| US-20090099213-A1 | Ortho-Condensed Pyridine and Pyrimidine Derivatives (e.g., Purines) as Protein Kinases Inhibitors | OXSR1, CDK1, CDK3 | CYP1A2 2933/4885TSHR 476/4885PI4KA 1245/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.